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Background: There is a need for reliable prognostic parameters in pulmonary arterial hypertension (PAH), es-
pecially in children. Pulsatile components of the right ventricular afterload, represented by pulmonary arte-
rial compliance (PACi) and pulmonary stroke volume (PSVi), may provide important additional prognostic
information to conventional static haemodynamic parameters. The aim of this study was to determine the
prognostic value of PACi and PSVi in paediatric PAH.
Methods: Right heart catheterization data of 52 consecutive paediatric idiopathic/hereditary PAH and PAH
associated with congenital heart disease patients with full haemodynamic evaluation seen at the Dutch na-
tional referral centre for paediatric pulmonary hypertension between 1993 and 2010 were reviewed. A con-
trol group was composed of patients with normal pulmonary vascular resistance. PSVi and PACi were
calculated and tested for predictive value for transplant-free survival.
Results: PAH patients had signiﬁcantly lower PSVi and PACi compared to control patients. PSVi and PACi were
lower in patients with higher WHO-functional class compared to those with lower functional classes. Higher
PSVi, PACi and mSAP and lower mPAP/mSAP and heart rate were associated with improved survival, inde-
pendent from WHO-functional class and PAH-targeted therapy. In multivariate analyses PSVi, heart rate
and mSAP emerged as the strongest haemodynamic predictors of survival. The effect of vasodilator challenge
on the haemodynamic variables did not provide additional prognostic information.
Conclusions: The parameters of both the pulsatile and static pulmonary circulations are strong independent
predictors for transplant-free survival, and therefore can be of complementary value in assessing disease
severity, predicting survival and guiding treatment in paediatric PAH.© 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
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Ltd. All rights reserved.(RV) failure and death. Despite emerging treatment options, PAH is
a progressive disease and data on its diagnosis, treatment and out-
come is limited, especially in children [1]. In PAH, treatment decisions
are based on the assessment of disease severity and prognosis by the
use of prognostic (surrogate-) parameters [2,3].
There is a strong need for reliable prognostic parameters that can be
used as clinical endpoints in order to guide the treatment of PAH. The
currently used parameters are far from perfect, especially in young
children with PAH. The World Health Organization functional class
(WHO-functional class) and 6-minute walk distance (6-MWD) are rec-
ognized as valuable prognostic parameters that are recommended to be
used in goal-oriented treatment strategies in adult PAH-patients [4–7].
In children, however, both parameters are often less reliable or not fea-
sible because of young age and/or impaired development [8]. Haemo-
dynamic parameters, such as pulmonary vascular resistance (PVR),
andmean pulmonary arterial pressure (mPAP), are important objective
measurements used to conﬁrm the diagnosis of PAH. Furthermore, they
may provide prognostic information. However, while invasive haemo-
dynamic evaluation in children frequently requires general anaesthesia,
1371J.M. Douwes et al. / International Journal of Cardiology 168 (2013) 1370–1377the correlation ofmPAP and PVRiwith clinical status and survival is lim-
ited [5,9–14].
Elevated RV afterload leading to RV failure is the main determi-
nant of mortality in PAH. RV afterload consists of static components
(PVR andmPAP) deﬁning net forward ﬂow, and pulsatile components
deﬁning ﬂow and pressure oscillations. Pulsatile components include
pulmonary arterial compliance (PAC), the ability of pulmonary arteries
to accommodate oscillatory changes in volume, and pulmonary stroke
volume (PSV), the amount of blood ejected in the pulmonary artery
per cardiac cycle. The latter differs from RV stroke volume in the
setting of intracardiac shunt or tricuspid regurgitation. Conventional
haemodynamic parameters such as mPAP and PVRi only partially repre-
sent RV afterload, since they represent its static components and ignore
its pulsatile components [9,15]. In healthy subjects the pulsatile compo-
nents contribute little to the RV afterload, due to the low resistance and
high compliance of the pulmonary circulation. However in PAH their
contribution to RV afterload becomes increasingly important due to
arterial stiffening and increased reﬂection waves [16,17]. PAC and PSV,
both reﬂecting pulsatile components of the RV afterload, may therefore
provide additional prognostic information in PAH.
Previous ﬁndings in adult PAH patients indicated that PAC and PSV
may be valuable predictors for prognosis in adult PAH [18–21]. In
paediatric PAH, PAC has previously been shown to be associated
with pulmonary vascular disease severity, however its prognostic
value for mortality is not clear [22–24]. The purpose of this study
was to determine the prognostic value of PSV and PAC in children
with idiopathic/hereditary PAH (IPAH/HPAH) and PAH associated
with congenital heart disease (PAH-CHD).
2. Methods
In the Netherlands, all paediatric PAH patients are referred to the University Medical
Centre Groningen, the national referral centre within the Dutch National Network for
Paediatric Pulmonary Hypertension. At the referral centre, the diagnosis of PAH is con-
ﬁrmed by heart catheterization, treatment strategies have evolved according to the ‘ESC
guidelines for the diagnosis and treatment of PAH’, and all patients are regularly seen at
standardized follow-up visits [2].
We retrospectively reviewed the diagnostic heart catheterization data of all paedi-
atric patients with IPAH/HPAH and PAH-CHD seen at the Dutch national referral centre
from 1993 to 2010. PAH was deﬁned as elevated mPAP≥25 mmHg at rest, with a pul-
monary capillary wedge pressure (mPCWP) ≤15 mmHg and elevated PVRi≥3 Wood
units·m2 measured during heart catheterization. Only patients who had a full baseline
haemodynamic assessment by heart catheterization were included in the study.
PAH-CHD patients were subdivided into three different groups, based on their circulatory
physiology: 1) patients with an unrestricted pre-tricuspid shunt (atrial septal defects);
2) patients with an unrestricted post-tricuspid shunt ([atrio]ventricular septal defects,
patent ductus arteriosus, or uncorrected univentricular heart with unobstructed pulmo-
nary blood ﬂow) and 3) patients with surgically corrected post-tricuspid shunt (without
residual shunts) in whom PAH developed or persisted after shunt-closure.
A control group, which was age- and shunt-matched in order to rule out both age
and circulatory physiology as possible confounding factors, was composed of patients
with low pulmonary vascular resistance (PVRib2.5 WU.m2), catheterized at the
University Medical Centre Groningen. The control group included control patients
with normal pulmonary circulation (patients with aortic stenosis) and shunt control
patients with increased pulmonary blood ﬂow index (Qpi/Qsi>1.2) due to persistent
ductus arteriosus, or atrial septal defects, with normal mPAP (b20 mmHg).
Our institutional human research committee approved the protocol for the Dutch
national clinical patient registry and the use of its data for observational studies. Patients
or their legal guardians provided informed consent. The authors of this manuscript have
certiﬁed that they comply with the Principles of Ethical Publishing in the International
Journal of Cardiology.
2.1. Baseline evaluation
Baseline evaluation included WHO-functional class and diagnostic heart catheter-
ization. Baseline haemodynamic measurements included mean right atrial pressure
(mRAP), mPAP, pulmonary arterial pulse pressure (PP), mPCWP, PVR indexed for
body surface area (PVRi), Qpi, pulmonary stroke volume index (PSVi) and pulmonary
arterial compliance index (PACi). Qpi was determined by using Fick's method, based
on estimated oxygen consumption (VO2). VO2 was estimated by using two methods:
(i) for patients b7 years of age VO2=1.39×Height(cm)+0.84×Weight(kg)−35.7
and (ii) for patients >7 years of age by the tables of Lafarge and Miettinen [25,26].
PVRi was determined by dividing the pulmonary arterial to venous pressure fall byQpi. The PSVi was determined by dividing Qpi by the heart rate, and ﬁnally PACi was
calculated by dividing PSVi by PP.
During heart catheterization, acute vasodilator challenge was performed by using
inhaled nitric oxide (NO), or NO with 100% O2. In the case of sequential pulmonary va-
sodilator response tests with both conditions, the maximal response of each individual
parameter was determined and used for analyses.2.2. Statistical analyses
Data are presented as mean±standard deviation, median (interquartile range) or
number (percentage) of patients. Patient characteristics and baseline haemodynamic
parameters were compared between PAH patients and controls and between IPAH/
HPAH and PAH-CHD patients, by using t-test for normally distributed variables,
Mann–Whitney U test for not-normally distributed data and Chi-square test for cate-
gorical variables. Analyses were performed by using SPSS 18.0 (SPSS Inc. Chicago, IL,
USA) and Stata 11 (Statacorp, College Station, Texas, USA). The level of signiﬁcance
was set to 0.05.
Survival analyses were based on transplant-free survival from haemodynamic
evaluation, with death and transplantation as end-points. Patients without end-point
were censored at last follow-up visit. Survival was evaluated by using Kaplan–Meier
curves and Log Rank tests. PACi, PSVi, mSAP and heart rate were split on their median
for analyses with Kaplan–Meier curves. Subsequently, the correlation of continuous
haemodynamic parameters and clinical parameters (WHO-class, diagnosis, shunt,
age, therapy) with survival was evaluated by using Cox regression. Backward multivar-
iate Cox regression was used to identify the strongest haemodynamic predictors for
survival. In multivariate analyses the haemodynamic predictors were corrected for
clinical parameters that were associatedwith survival in univariate analyses. All variables
met the proportionality assumptions and there were no statistical interactions between
variables that were combined in multivariable analyses.3. Results
3.1. Patient characteristics
Fifty-two paediatric PAH patients (31 female, 21 male) and 17
control patients (6 female and 11 male) were included in this study.
There were 32 IPAH/HPAH and 20 PAH-CHD patients (15 with post-
tricuspid shunt, 1 with pre-tricuspid shunt and 4 with corrected shunt).
Median age of the PAH patients was 7.1 years. The distribution of gender,
age and shunt types did not differ between the PAH patients and the con-
trol group (Table 1).
Patients were treated according to the evolving guidelines for di-
agnosis and treatment of pulmonary hypertension [2]. Nine patients
did not receive PAH-targeted therapy because they were diagnosed
and died in the era in which PAH-targeted therapy (endothelin recep-
tor antagonist, PDE5-inhibitor or prostacyclin derivate) was not yet
available in the Netherlands. There were 23 patients on mono, and
20 patients on combination (dual or triple) PAH-targeted therapy.3.2. Haemodynamics
The PAH patients had severe PAH with elevated mPAP and PVRi
(Table 2). In contrast, control subjects without a pulmonary to systemic
shunt had normal mPAP, PVRi and Qpi. Control subjects with a pre-
or post-tricuspid shunt had increased Qpi (median 6.9 L/min/m2)
due to left to right shunting, accompanied by a low PVRi (range
0.5–1.1 WU.m2) and normal mPAP (range 10–17 mmHg). The mSAP
of the control patients was comparable to the PAH patients, reﬂecting
a successful patient matching procedure. The PSVi and PACi were
both signiﬁcantly decreased in the PAH patients compared to the con-
trols. Except for the aorta saturation, there were no signiﬁcant differ-
ences in baseline haemodynamics between the IPAH/HPAH and
PAH-CHD patients. Both PSVi and PACi were lower in patients with
higher WHO-functional class (Fig. 1).
41 (79%) PAH patients were tested for acute pulmonary vasodilator
response. The mPAP, mPAP/mSAP and PVRi signiﬁcantly decreased
during acute vasodilator response (Table 3), whereas mean pulmonary
arterial pulse pressure did not signiﬁcantly change. Both PSVi and PACi
increased signiﬁcantly during acute vasodilator response testing.
Table 1
Baseline characteristics.
All patients
(n=52)
Control patients
(n=17)
P-value⁎ IPAH/HPAP
(n=32)
PAH-CHD
(n=20)
P-value†
Age at right heart catheterization (yrs) 7.1 (3.1;13.3) 7.1 (3.7;12.1) 0.99 7.6 (3.8;14.0) 7.0 (2.0;11.8) 0.27
Follow-up time (yrs) 3.9 (1.6;7.0) 3.7 (0.7;7.0) 4.1 (2.6;6.9) 0.73
Sex male 21 (40) 11 (65) 0.10 16 (50) 5 (25) 0.09
WHO-Functional class
I 1 (2) 0 (0) 1 (5) 0.82
II 17 (33) 12 (38) 5 (25)
III 26 (50) 15 (47) 11 (55)
IV 8 (15) 5 (16) 3 (15)
Shunt
No shunt 36 (69) 11 (65) 0.69 32 (100) 4 (20) b0.01a
Pre-tricuspid shunt 1 (2) 1 (6) 1 (5)
Post-tricuspid shunt 15 (29) 5 (29) 15 (75)
Values are in median (interquartile range) or n (%) as appropriate.
Comparison between ⁎all patients versus control patients and †IPAH/HPAH versus PAH-CHD with Mann–Whitney U test, Chi-square tests or Fisher's exact test as appropriate.
IPAH/HPAH, idiopathic or hereditary pulmonary arterial hypertension; PAH-CHD, pulmonary arterial hypertension associated with congenital heart disease; yrs, years; WHO,
World Health Organization.
a Signiﬁcant test result.
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The patients in our cohort had regular standardized follow-up visits,
with a median follow-up time of 3.9 years (interquartile range
1.6–7.0 years). Considering the small number of patients with more
than 7 years of follow-up (25%, 13 patients), survival analyses were
truncated at 7 years of follow-up. The 1-, 2-, and 5-year survival rates
of the cohort were 88%, 86%, and 68%, respectively. No difference in sur-
vival between the iPAH/HPAH and PAH-CHD patient group could be
demonstrated (Fig. 2). Kaplan–Meier curves showed that a higher
PSVi and a higher PACi were associated with better survival (Fig. 3A).
Furthermore, higher mSAP and lower heart rate were associated with
improved survival (Fig. 3B). The associations of PACi, PSVi, mSAP and
heart rate with survival were not explained by differences in distribu-
tion of diagnosis, patients with HPAH or patients treated with prostacy-
clin derivate, between the percentile groups. Furthermore, therewas no
indication that the strength of these associations differed between the
diagnosis subgroups.
In univariate Cox regression analyses higher PSVi, higher PACi, lower
mPAP/mSAP, lower heart rate (during general anaesthesia) and higher
mSAPwere associatedwith better survival (Table 4). In contrast, mPAP,
PVRI, Qpi and Qsi did not show a signiﬁcant associationwith survival. InTable 2
Baseline haemodynamic measurements.
All patients
(n=52)
Contro
(n=1
Heart rate 79 (69;106) 85 (71
Aortic oxygen saturation (%) 96 (88;99) 100 (9
Mean right atrial pressure (mmHg) 6 (5;8) 5 (4;6
Mean pulmonary arterial pressure (mmHg) 51±19 13±3
Mean systemic arterial pressure (mmHg) 60±13 63±1
mPAP/mSAP 0.9±0.3 0.2±0
Pulmonary blood ﬂow index (l/min/m2) 2.8 (2.3;3.8) 5.5 (3
Systemic blood ﬂow index (l/min/m2) 2.8 (2.3;3.7) 4.1 (3
Qpi/Qsi 1.0 (0.9;1.0) 1.0 (1
Pulmonary vascular resistance index (WU.m2) 14.6 (7.2;22.2) 0.7 (0
Systemic vascular resistance index (WU.m2) 18.2 (13.5;22.3) 13.5 (
PVR/SVR 0.8 (0.5;1.1) 0.1 (0
Pulmonary stroke volume index (ml/m2) 32.9 (27.3;44.3) 60.2 (
Pulse pressure (mmHg) 40±13 10±2
Pulmonary arterial compliance index (ml/mm Hg/m2) 0.9 (0.6;1.3) 6.5 (4
Values are in median (interquartile range) or mean±SD as appropriate.
Comparison between ⁎all patients versus control patients and †IPAH/HPAH versus PAH-CH
IPAH/HPAH, idiopathic or hereditary pulmonary arterial hypertension; PAH-CHD, pulmonary art
l/min/m2, litre per minute per squaremetre;WU,Wood units; mPAP/mSAP, mean pulmonary to
systemic vascular resistance ratio.
a Signiﬁcant test result.a backward stepwisemultivariate Cox regression analysis including the
haemodynamic variables that were associated with survival in univari-
ate analysis, PSVi, heart rate and mSAP emerged as the strongest
haemodynamic predictors for survival in this series of paediatric PAH.
Patients inWHO-functional class IV hadworse survival compared to
patients in WHO-functional classes I–III. Patients on PAH-targeted
mono or combination therapy had better survival compared to patients
for whom PAH-targeted therapy was not yet available. Therefore, sub-
sequently, haemodynamic variables that were demonstrated to have
an association with survival were corrected for WHO-functional class
and PAH-targeted therapy in multivariate Cox regression analyses.
These analyses showed that higher PSVi, higher PACi, lower heart rate,
lower mPAP/mSAP and higher mSAP were associated with improved
survival independent from WHO-functional class and PAH-targeted
therapy (Table 4). Younger patients tended to haveworse survival com-
pared to older patients. In order to adjust the survival analysis for the ef-
fect of age on mSAP and heart rate, the multivariate analyses were
additionally corrected for age (Table 4). After correction for age, the
point estimates of the associations remained the same, indicating that
the associations were independent from age.
Two of the IPAH/HPAH patients (6.3%) showed acute vasodilator
response according to the response criteria of the ESC guidelines [2].l patients
7)
P-value⁎ IPAH/HPAP
(n=32)
PAH-CHD
(n=20)
P-value†
;98) 0.82 79 (67;107) 77 (70;104) 0.87
9;100) b0.01a 98 (94;99) 90 (83;94) 0.01a
) 0.03a 6 (5;8) 6 (5;8) 0.69
b0.01a 51±20 51±16 0.95
2 0.47 62±13 57±13 0.18
.1 b0.01a 0.9±0.4 0.9±0.2 0.61
.5;6.3) b0.01a 2.6 (2.2;3.5) 2.9 (2.3;4.2) 0.34
.4;5.4) b0.01a 2.8 (2.3;3.5) 2.5 (2.3;3.8) 0.96
.0;1.3) 0.05 1.0 (0.9;1.0) 1.0 (0.9;1.3) 0.15
.6;1.0) b0.01a 14.0 (7.1;26.9) 14.6 (8.3;19.0) 0.76
11.6;18.3) 0.03a 17.7 (14.0;25.6) 18.2 (11.9;21.7) 0.46
.0;0.1) b0.01a 0.8 (0.4;1.1) 0.8 (0.5;1.1) 0.96
46.1;78.6) b0.01a 32.9 (26.2;42.6) 35.6 (27.9;46.4) 0.62
b0.01a 40±14 39±12 0.70
.9;7.7) b0.01a 0.9 (0.6;1.2) 0.9 (0.7;1.3) 0.61
D with Mann–Whitney U test or T-test for independent samples as appropriate.
erial hypertension associatedwith congenital heart disease;mmHg,millimetres of mercury;
systemic pressure ratio; Qpi/Qsi, pulmonary to systemic ﬂow ratio; PVR/SVR, pulmonary to
Fig. 1. PSVi and PACi for WHO-functional class subgroups. Scatter plot with indications of median and interquartile ranges of PSVi and PACi, respectively, for WHO-functional class
subgroups. P-values derived from Kruskal–Wallis test. PSVi, pulmonary stroke volume index; PACi, pulmonary arterial compliance index; WHO-functional class, World Health
Organization functional class.
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tended to have improved survival compared to non-responders. Howev-
er, individual haemodynamic variables during acute pulmonary vasodi-
lator response testing did not provide additional information to the
prognostic value of their baseline values.Table 3
Acute vasodilator response test.
IPAH/HPAH
(n=26)
mPAP Baseline 51±21
Maximal change −5±9
Maximal response 46±21
mPAP/mSAP Baseline 0.8±0.3
Maximal change −0.1±0.2
Maximal response 0.7±0.4
Qpi Baseline 2.5 (2.2;3.2)
Maximal change 0.2 (−0.0;0.7)
Maximal response 2.9 (2.2;3.9)
Qsi Baseline 2.8 (2.3;3.3)
Maximal change 0.2 (−0.0;0.6)
Maximal response 2.9 (2.3;3.9)
PVRi Baseline 14.8 (7.9;27.8)
Maximal change −3.0 (−4.9;−0.9)
Maximal response 10.1 (4.1;20.1)
PVR/SVR Baseline 0.8 (0.5;1.1)
Maximal change −0.2 (−0.3;−0.1)
Maximal response 0.6 (0.3;0.8)
PSVi Baseline 32.5 (27.5;41.5)
Maximal change 4.8 (2.3;8.7)
Maximal response 39.1 (33.2;52.3)
PAPP Baseline 40±14
Maximal change −3.7±11.8
Maximal response 36±17
PACi Baseline 0.9 (0.6;1.1)
Maximal change 0.1 (0.1;0.5)
Maximal response 1.0 (0.8;2.2)
Values are in median (interquartile range) or mean±SD as appropriate. Comparison betwe
signed rank test or paired T-test as appropriate.
mPAP, mean pulmonary arterial pressure; mPAP/mSAP, mean pulmonary to systemic pressu
resistance index; PVR/SVR, pulmonary to systemic vascular resistance ratio; PSVi, pulmon
arterial compliance index.
a Signiﬁcant test result.4. Discussion
Despite the introduction of PAH-targeted therapy, paediatric PAH is
still a severe disease with a detrimental prognosis, illustrated by reported
survival rates in the current era [11,13]. Conventional haemodynamicPAH-CHD
(n=15)
All patients
(n=41)
P-value
51±15 51±19
−1±4 −3±7
50±16 47±19 b0.01a
0.9±0.2 0.9±0.3
−0.0±0.1 −0.1±0.2
0.9±0.2 0.8±0.4 b0.01a
2.7 (2.2;3.8) 2.6 (2.2;3.3)
0.4 (−0.2;1.2) 0.2 (−0.0;0.7)
2.7 (2.2;4.9) 2.9 (2.2;4.1) b0.01a
2.7 (2.3;4.2) 2.8 (2.3;3.8)
−0.4 (−0.6;−0.2) 0.0 (−0.3;0.3)
2.4 (2.2;3.6) 2.9 (2.3;3.7) 0.73
15.7 (10.0;19.4) 15.7 (8.8;26.0)
−1.7 (−6.3;0.4) −2.9 (−4.9;−0.9)
14.8 (6.7;24.4) 11.7 (5.1;20.1) b0.01a
0.9 (0.6;1.4) 0.9 (0.5;1.1)
−0.2 (−0.5;0.0) −0.2 (−0.3;−0.0)
0.6 (0.4;0.9) 0.6 (0.3;0.9) b0.01a
30.4 (22.5;43.2) 32.0 (27.1;42.1)
6.1 (−0.2;12.7) 5.3 (2.2;9.9)
37.2 (26.5;46.5) 38.6 (31.3;48.4) b0.01a
38±13 39±14
0.5±4.5 −2.2±9.9
39±12 37±15 0.16
0.8 (0.6;1.3) 0.8 (0.6;1.1)
0.1 (−0.0;0.3) 0.1 (0.1;0.4)
0.9 (0.7;1.4) 1.0 (0.8;1.5) b0.01a
en baseline and maximal vasodilator responses in the all patients group with Wilcoxon
re ratio; Qpi, pulmonary ﬂow index; Qsi, systemic ﬂow index; PVRi, pulmonary vascular
ary stroke volume index; PAPP, pulmonary arterial pulse pressure; PACi, pulmonary
Fig. 2. Survival of the study group. Kaplan–Meier curves showing the survival of all included PAH patients (left) and stratiﬁed for diagnosis subgroup (right). PAH, pulmonary arterial
hypertension; PAH-CHD, pulmonary arterial hypertension associated with congenital heart disease; IPAH/HPAH, idiopathic or hereditary pulmonary arterial hypertension.
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ited prognostic information. This study shows that pulsatile components
of RV afterload provide important additional prognostic information.
The predictive value of PACi and PSVi for survival can be explained
by their increasingly important role in pulsatile ﬂow and RV afterload
in PAH [16]. High compliant pulmonary arteries can reduce pulmonary
arterial pressures and ﬂow velocities, thereby delaying reﬂecting pres-
sure waves. Reduced compliance leads to higher pressures, higher
ﬂow rate and early reﬂection waves, thereby increasing RV workload,
which ultimately results in RV failure. Therefore in PAH, PACi reﬂects
an important part of the RV afterload.
Since PACi and PVRi determine the ability of the pulmonary arter-
ies to accommodate blood ﬂow, a reduced PACi and increased PVRi
leads to reduced PSVi. Increased RV afterload and the accompanying
increased RV work load and hypertrophy in PAH, may eventually de-
crease PSVi even further [27]. One could question whether the associ-
ation between PSVi and survival is driven by RV function or by
progression of the pulmonary vascular disease. This is a complex
issue, especially in a patient group with heterogeneous complex con-
genital heart diseases. The current data show that the association of
PSVi with outcome was found not only in IPAH/HPAH, but also in
PAH-CHD patients with a shunt at post-tricuspid level. In the latter
patient group, PSVi is not synonymous to RV stroke volume due to
right to left shunting and thus PSVi does not simply reﬂect RV func-
tion. In patients with intracardiac shunts, PSVi was associated with
survival. Furthermore, there was no indication that the strength of
the found associations with survival in PAH-CHD patients differed
from that in iPAH/HPAH patients. These ﬁndings support the notion
that PSVi seems to represent a function of pulmonary vascular disease
rather than of RV function.
PACi and PSVi both reﬂect disease severity in paediatric PAH. They
are likely to decrease during disease progression of PAH and are
candidate-parameters to assess disease severity and treatment ef-
fects. PSVi may more fully represent the progression of the vascular
disease than PACi, since PSVi is determined by the RV afterload as a
whole, including vascular resistance, arterial compliance and reﬂec-
tion waves, whereas PACi predominantly represents pulmonary arte-
rial compliance. This may explain why our analyses indicates that
PSVi is the stronger prognostic parameter in paediatric PAH com-
pared to PACi.
Higher PACi was associated with improved survival independent
from WHO-functional class and therapy, which is in congruence withprevious reports in adult PAH [18,19]. Sajan et al. [28] showed that in
children with PAH, worse survival was predicted by either a higher or
a lower than average PACi. In contrast, in the present study, the associ-
ation between PACi and survival showed to be more linear. The reason
for this disparity may lay in the difference in the composition of the
study groups. Sajan et al. [28] included a large group of PAH-CHD pa-
tients with high PACi and it was unclear whether these patients all
had advanced, irreversible PAH, whereas in the current study, all
PAH-CHD patients had advanced irreversible PAH.
Higher PSVi was associated with improved survival in our study. RV
stroke volumemeasured by pulmonary arterialMRI or by Fick'smethod
has previously been shown to be a valuable prognostic factor in adult
IPAH/HPAH [20]. In earlier reports cardiac index has been shown to be
a prognostic parameter in iPAH. However, PSVi showed to be a stronger
predictor of survival in both paediatric and adult PAH [4,13,20]. This can
be explained by the fact that a decreased PSVi can be compensated by
an increased heart rate, thereby maintaining cardiac output. The latter
will affect the association of cardiac indexwith survival [20]. This notion
is supported by the association of higher heart rate with decreased sur-
vival as found in the current study.
The investigated patient cohort included patients for whom ad-
vanced PAH therapy was not yet available. Evolving treatment strate-
gies may inﬂuence outcome and survival analyses. The analyses were
corrected for this potentially confounding effect of treatment and the
prognostic value of PACi and PSVi showed to be independent from
treatment. This indicates that these associations were not affected
by the evolving treatment strategies.
In this study the conventional, static parameters mPAP and PVRi
were not associated with survival. PVRi and mPAP are important ob-
jective parameters in the conﬁrmation of the diagnosis and assess-
ment of disease severity in PAH. Although reports on the prognostic
value of mPAP and PVRi in PAH are inconsistent, several studies in
paediatric PAH have shown a lack of signiﬁcant prognostic value of
mPAP and/or PVRi in these patients. In paediatric PAH, PACi and
PSVi appeared to be stronger predictors of survival compared to
mPAP and PVRi. Therefore, in the clinical situation PACi and PSVi
can provide prognostic information additional to conventional
haemodynamic measurements, potentially improving goal-oriented
treatment strategies.
In addition to PACi and PSVi, lower mPAP/mSAP, lower heart rate,
and higher mSAP were associated with improved survival in our
study. The association of mPAP/mSAP with survival is in congruence
Fig. 3. A) Survival stratiﬁed for PSVi and PACi. Kaplan–Meier curves with log rank tests showing the survival of all included PAH patients stratiﬁed for the median of pulmonary
stroke volume index (PSVi, left) and pulmonary arterial compliance index (PACi, right). B) Survival stratiﬁed for mSAP and heart rate Kaplan–Meier curves with log rank tests showing
the survival of all included PAH patients stratiﬁed for the median of mean systemic arterial pressure (mSAP, left) and heart rate (HR, right).
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with poorer outcome in paediatric PAH [13,29]. Since the associations
of PACi and PSVi with survival were more stable in multivariate anal-
ysis than that of mSAP, mPAP/mSAP and heart rate, these pulsatile pa-
rameters seem to have a stronger prognostic value.
Heart rate andmSAP are affected by children's age, which by itself is
associatedwith outcome in paediatric PAH [12]. Therefore agemay par-
tially explain their association with survival. In this study, the point es-
timates of the survival analyses remained numerically the same when
corrected for age. Therefore the associations of heart rate, PACi, PSVi,
mSAP and mPAP/mSAP with survival appear age independent.
The association of heart rate with survival, previously reported in
adult PAH, may provide important clinical advantages [30,31]. Heart
rate is a non-invasive, easily obtainable parameter suitable for multi-
ple follow-up measurements in paediatric PAH. Therefore heart rate
may potentially be a valuable parameter to assist in guiding therapy
in paediatric PAH.
Heart rate may both determine and respond to stroke volume of
the RV, LV or both combined and with that it is strongly relatedwith PSVi. Despite this intimate relation, both parameters appeared
independent predictors of survival in this study. Therefore both pa-
rameters may have complementary value in guiding treatment.4.1. Study limitations
Our analyses were limited by the relatively small number of pa-
tients. Nevertheless, we found strong correlations between survival
and the pulsatile haemodynamic variables. In paediatric pulmonary
hypertension, a very rare disease, patient numbers and data regarding
survival and prognostic parameters are extremely limited. Therefore
this study contributes largely to the currently available data.
Furthermore, no paired case-control matching could be performed
due to the low number of available control patients. Congenital heart
defects associated with systemic to pulmonary shunts and low PVRi
are currently corrected at an early age before PVRi rises, leaving virtually
no older patients with an important shunt and low PVR. Therefore a
frequency matching approach was applied.
Table 4
Cox regression analyses for transplant-free survival.
Univariate analyses Multivariate analyses† Multivariate analyses‡
HR (95%-CI) P-value HR (95%-CI) P-value HR (95%-CI) P-value
Mean pulmonary arterial pressureb 1.01 (0.98–1.04) 0.533
Mean systemic arterial pressureb 0.94 (0.89–0.99) 0.016a 0.93 (0.86–1.00) 0.042a 0.95 (0.88–1.02) 0.186
mPAP/mSAP ratioc 1.34 (1.07–1.68) 0.010a 1.44 (1.41–1.82) 0.002a 1.36 (1.05–1.77) 0.020a
Pulmonary vascular resistance indexd 1.03 (0.99–1.07) 0.121
Pulmonary blood ﬂow indexe 0.79 (0.46–1.34) 0.374
Systemic blood ﬂow indexe 0.62 (0.32–1.21) 0.159
Pulmonary arterial compliance indexf 0.84 (0.72–0.98) 0.027a 0.81 (0.68–0.98) 0.031a 0.83 (0.68–1.01) 0.063
Pulmonary stroke volume indexg 0.70 (0.55–0.89) 0.004a 0.70 (0.53–0.93) 0.014a 0.73 (0.54–0.98) 0.034a
Heart rateh 1.36 (1.14–1.63) 0.001a 1.51 (1.16–1.97) 0.002a 1.43 (1.02–2.00) 0.040a
WHO-class IV vs. I–III 3.41 (1.11–10.43) 0.032a
Therapy
No therapy Reference group
Mono therapy 0.33 (0.10–1.04) 0.059
Combination therapy 0.05 (0.01–0.44) 0.007a
Agei 0.89 (0.79–1.00) 0.056
Univariate and multivariate Cox regression analyses. Haemodynamic variables with a signiﬁcant relation to survival in univariate test, were separately corrected for †therapy and
WHO-class and ‡therapy, WHO-class, and age. mPAP/mSAP, mean pulmonary to systemic pressure ratio; WHO, World Health Organization. HR, hazard ratio.
a Signiﬁcant test result.
b HR per 1 mmHg change in pressure.
c HR per 0.1 change in mPAP/mSAP.
d HR per 1 WU.m2 change in PVRi.
e HR per 1 ml/m2 change in ﬂow index.
f HR per 0.1 ml/mmHg change in PACi.
g HR per 5 ml change in PSVi.
h HR per 10 bpm change in heart rate.
i HR per 1 year change in age.
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In conclusion, parameters of the pulsatile pulmonary circulation,
such as PACi and PSVi, are associated with disease severity and pre-
dict survival in paediatric PAH, independent from conventional clini-
cal prognostic parameters, such as PVRi. Therefore these parameters
can be of complementary value to more conventional haemodynamic
parameters in assessing disease severity, predicting survival and
guiding treatment in paediatric PAH.
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